Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
News|Articles|January 6, 2016
Takeda Acquires US Biologics Manufacturing Facility
Author(s)Pharmaceutical Technology Editors
Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.
Advertisement
Takeda Pharmaceutical Company Limited announced the acquisition of a Brooklyn Park, Minnesota-based biologics manufacturing facility from Baxalta Inc in a Jan. 6, 2016 press announcement.
Takeda is a Japan-based pharmaceutical company focused on research and development. It is the largest pharmaceutical company in Japan.
According to the company, Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products. FDA approved Entyvio in May 2014 for the treatment of ulcerative colitis and moderate-to-severe Crohn’s disease.
Terms of the transaction were not disclosed.
Source:
Advertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Rare Disease Framework Puts CMC Review in Scope
2
Clinical Trial Delays: FDA’s Expedited IND Pilot vs China’s 818 Decree
3
PharmTech AI Pulse Check: AI Watermark Vulnerability
4
Manufacturing Intelligence: What FDA's Real-World Use Case Database Means for CMC
5